TY - JOUR
T1 - The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia
AU - Morabito, Fortunato
AU - De Filippi, Rosaria
AU - Laurenti, Luca
AU - Zirlik, Katja
AU - Recchia, Anna Grazia
AU - Gentile, Massimo
AU - Morelli, Emanuela
AU - Vigna, Ernesto
AU - Gigliotti, Vincenzo
AU - Calemma, Rosa
AU - Amoroso, Barbara
AU - Neri, Antonino
AU - Cutrona, Giovanna
AU - Ferrarini, Manlio
AU - Molica, Stefano
AU - Del Poeta, Giovanni
AU - Tripodo, Claudio
AU - Pinto, Antonio
PY - 2011/12/8
Y1 - 2011/12/8
N2 - Identification of patients at risk of early disease progression is the mainstay of tailored management in chronic lymphocytic leukemia (CLL). Although application of established biomarkers is limited by intrinsic detection/readout complexities, abnormality of κ and λ serum-free light chain ratio [sFLC (κ/λ)] was proposed as a straightforward prognosticator in CLL. By analyzing 449 therapy-naive patients, we show that an abnormal sFLC(κ/λ), along with CD38, ZAP-70, IGHV mutations, cytogenetics and stage, independently predicts treatment-free survival (TFS) but becomes prognostically irrelevant if the cumulative amount of clonal and nonclonal FLCs [sFLC(κ + λ)], a variable associated with cytogenetic risk, exceeds the threshold of 60.6 mg/mL. Patients with sFLC(κ + λ) above cutoff displayed a poorer TFS outcome, irrespective of sFLC(κ/λ). Only ZAP-70, cytogenetics, stage, and TFS remained associated with sFLC(κ + λ) in a multivariate model. By assigning 1 point each for these variables, the 3-year probability of TFS was 94.8%, 84.5%, 61.6%, and 21.1% for patients scoring 0, 1, 2, and 3 + 4, respectively (P <.0001). These data, and the demonstration that monoclonal and polyclonal B cells concur to FLC synthesis in tumor tissues, suggest that sFLC(κ/λ) and sFLC(κ + λ) mirror distinct biologic processes in CLL. sFLC(κ + λ) assessment represents a sensitive and cost-effective tool for identifying CLL patients requiring early treatment.
AB - Identification of patients at risk of early disease progression is the mainstay of tailored management in chronic lymphocytic leukemia (CLL). Although application of established biomarkers is limited by intrinsic detection/readout complexities, abnormality of κ and λ serum-free light chain ratio [sFLC (κ/λ)] was proposed as a straightforward prognosticator in CLL. By analyzing 449 therapy-naive patients, we show that an abnormal sFLC(κ/λ), along with CD38, ZAP-70, IGHV mutations, cytogenetics and stage, independently predicts treatment-free survival (TFS) but becomes prognostically irrelevant if the cumulative amount of clonal and nonclonal FLCs [sFLC(κ + λ)], a variable associated with cytogenetic risk, exceeds the threshold of 60.6 mg/mL. Patients with sFLC(κ + λ) above cutoff displayed a poorer TFS outcome, irrespective of sFLC(κ/λ). Only ZAP-70, cytogenetics, stage, and TFS remained associated with sFLC(κ + λ) in a multivariate model. By assigning 1 point each for these variables, the 3-year probability of TFS was 94.8%, 84.5%, 61.6%, and 21.1% for patients scoring 0, 1, 2, and 3 + 4, respectively (P <.0001). These data, and the demonstration that monoclonal and polyclonal B cells concur to FLC synthesis in tumor tissues, suggest that sFLC(κ/λ) and sFLC(κ + λ) mirror distinct biologic processes in CLL. sFLC(κ + λ) assessment represents a sensitive and cost-effective tool for identifying CLL patients requiring early treatment.
UR - http://www.scopus.com/inward/record.url?scp=83455210395&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=83455210395&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-04-345587
DO - 10.1182/blood-2011-04-345587
M3 - Article
C2 - 21998207
AN - SCOPUS:83455210395
VL - 118
SP - 6353
EP - 6361
JO - Blood
JF - Blood
SN - 0006-4971
IS - 24
ER -